-

Galderma Launches CETAPHIL® Line for Sensitive Skin and New DAYLONG® Sun Protection Product in Switzerland

  • CETAPHIL quality dermatology line for sensitive skin is now available in Swiss pharmacies and drugstores
  • DAYLONG, a market-leading sun protection brand, is expanded to include practical DAYLONG Sun to Go cream and stick SPF 50+

LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma has expanded its consumer care portfolio in Switzerland, where the global dermatology company originated and is headquartered. The expansion offers consumers more options for their dermatology needs. The move includes the introduction of the dermatologist-recommended CETAPHIL® line for sensitive skin, as well as the expansion of the DAYLONG® brand for sun protection.

CETAPHIL is now available in Switzerland

CETAPHIL, the sensitive skincare line recommended by dermatologists worldwide, is now available in Switzerland, exclusively in pharmacies and drugstores. The entry of the CETAPHIL range into the dermo-cosmetic market means consumers now have more choice of topical skincare for sensitive skin.

Swiss consumers can now purchase the core range of CETAPHIL moisturizing creams, moisturizing lotion and gentle skin cleanser. Additionally, the CETAPHIL PRO range for special skin conditions completes the CETAPHIL portfolio. The brand enters the dermo-cosmetic market as a complementary addition to medicine products.

DAYLONG brings new packaging and product to the market

Galderma’s DAYLONG range, a market leader in sun protection in Switzerland, has expanded just in time for May, which is Skin Cancer Awareness Month.

DAYLONG Face Sun to Go Lotion and Stick is practical to carry and easy to apply, offering SPF 50+ for strong protection against UVA, UVB and IR rays.

The whole DAYLONG portfolio also gets a fresh, youthful new look. DAYLONG Sensitive and DAYLONG Sport – product ranges with a proven track record in sun protection – can now be found in a modern clear packaging design, developed in collaboration with Swiss consumers.

"Galderma has been caring for the sensitive skin of millions of people worldwide, and we are excited to expand our offering in Switzerland, our home country.
These launches demonstrate Galderma’s commitment to continual development and enhancement of our brands.”WALTER GEIGER
HEAD OF CONSUMER BUSINESS UNIT GALDERMA

About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended in Germany and the #1 dermatologist-recommended facial skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day.

About DAYLONG
Synonymous with Swiss values of continuous research and high-quality, the DAYLONG range is one of the market leaders for sun protection in Switzerland. Since 1993, scientists and experts have worked continuously to develop existing products and is now focused on enhancing their sustainability.

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com

CETAPHIL® is a registered trademark of Galderma Holding AG. Daylong® is a registered trademark of Galderma SA.

Contacts

Media Contact
Lauren Starr
Head of Franchise Communications
media@galderma.com

Galderma


Release Summary
Galderma launches CETAPHIL® line for sensitive skin and new DAYLONG® sun protection product in Switzerland.
Release Versions

Contacts

Media Contact
Lauren Starr
Head of Franchise Communications
media@galderma.com

More News From Galderma

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from impr...

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint...

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16. Six poster presentations spotlighted the latest data on Restylane, Sculptra, and Relfydess*, while a series of onsite educational events through the Galderma Aesthetic Injector Network (GA...
Back to Newsroom